Trade Protara Therapeutics, Inc. - TARA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Protara Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.53 |
Open* | 1.65 |
1-Year Change* | -45.54% |
Day's Range* | 1.58 - 1.67 |
52 wk Range | 1.12-4.18 |
Average Volume (10 days) | 45.15K |
Average Volume (3 months) | 618.99K |
Market Cap | 12.96M |
P/E Ratio | -100.00K |
Shares Outstanding | 11.36M |
Revenue | N/A |
EPS | -6.13 |
Dividend (Yield %) | N/A |
Beta | 1.07 |
Next Earnings Date | Mar 6, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 1.53 | 0.16 | 11.68% | 1.37 | 1.59 | 1.37 |
Dec 7, 2023 | 1.35 | -0.05 | -3.57% | 1.40 | 1.41 | 1.35 |
Dec 6, 2023 | 1.39 | 0.03 | 2.21% | 1.36 | 1.39 | 1.35 |
Dec 5, 2023 | 1.36 | -0.03 | -2.16% | 1.39 | 1.43 | 1.32 |
Dec 4, 2023 | 1.37 | -0.04 | -2.84% | 1.41 | 1.44 | 1.34 |
Dec 1, 2023 | 1.40 | 0.02 | 1.45% | 1.38 | 1.43 | 1.37 |
Nov 30, 2023 | 1.38 | 0.02 | 1.47% | 1.36 | 1.49 | 1.24 |
Nov 29, 2023 | 1.47 | 0.06 | 4.26% | 1.41 | 1.60 | 1.41 |
Nov 28, 2023 | 1.39 | 0.11 | 8.59% | 1.28 | 1.39 | 1.28 |
Nov 27, 2023 | 1.31 | 0.14 | 11.97% | 1.17 | 1.31 | 1.17 |
Nov 24, 2023 | 1.15 | -0.01 | -0.86% | 1.16 | 1.18 | 1.13 |
Nov 22, 2023 | 1.08 | -0.04 | -3.57% | 1.12 | 1.13 | 1.04 |
Nov 21, 2023 | 1.12 | -0.01 | -0.88% | 1.13 | 1.17 | 1.12 |
Nov 20, 2023 | 1.12 | 0.01 | 0.90% | 1.11 | 1.16 | 1.11 |
Nov 17, 2023 | 1.12 | -0.01 | -0.88% | 1.13 | 1.18 | 1.10 |
Nov 16, 2023 | 1.12 | -0.04 | -3.45% | 1.16 | 1.21 | 1.10 |
Nov 15, 2023 | 1.18 | 0.02 | 1.72% | 1.16 | 1.22 | 1.14 |
Nov 14, 2023 | 1.17 | 0.05 | 4.46% | 1.12 | 1.19 | 1.12 |
Nov 13, 2023 | 1.13 | 0.00 | 0.00% | 1.13 | 1.14 | 1.11 |
Nov 10, 2023 | 1.14 | -0.05 | -4.20% | 1.19 | 1.19 | 1.06 |
Protara Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, March 6, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Protara Therapeutics Inc Earnings Release Q4 2023 Protara Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 67.062 | 47.489 | 34.444 | 15.254 | 21.372 |
Selling/General/Admin. Expenses, Total | 20.627 | 26.401 | 22.462 | 8.816 | 9.524 |
Research & Development | 16.671 | 21.088 | 11.982 | 6.438 | 11.848 |
Operating Income | -67.062 | -47.489 | -34.444 | -15.254 | -21.372 |
Interest Income (Expense), Net Non-Operating | 1.11 | 0.237 | 0.466 | 0.262 | 0.436 |
Other, Net | 0 | 0.207 | |||
Net Income Before Taxes | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Net Income After Taxes | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Net Income Before Extra. Items | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Net Income | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Total Adjustments to Net Income | 0 | ||||
Income Available to Common Excl. Extra. Items | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Income Available to Common Incl. Extra. Items | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Diluted Net Income | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Diluted Weighted Average Shares | 11.2596 | 11.2326 | 7.23391 | 0.49728 | 0.45256 |
Diluted EPS Excluding Extraordinary Items | -5.85739 | -4.20669 | -4.69704 | -30.1483 | -45.8044 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -3.2359 | -4.20669 | -4.69704 | -30.1483 | -45.8044 |
Total Extraordinary Items | |||||
Depreciation / Amortization | 0.247 | ||||
Unusual Expense (Income) | 29.517 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 12.14 | 9.732 | 39.509 | 7.974 | 8.705 |
Selling/General/Admin. Expenses, Total | 4.893 | 4.589 | 5.003 | 4.508 | 5.621 |
Research & Development | 7.247 | 5.143 | 4.989 | 3.466 | 3.084 |
Operating Income | -12.14 | -9.732 | -39.509 | -7.974 | -8.705 |
Interest Income (Expense), Net Non-Operating | 0.846 | 0.687 | 0.542 | 0.283 | 0.166 |
Net Income Before Taxes | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Net Income After Taxes | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Net Income Before Extra. Items | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Net Income | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Income Available to Common Excl. Extra. Items | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Income Available to Common Incl. Extra. Items | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Diluted Net Income | -11.294 | -9.045 | -38.967 | -7.691 | -8.539 |
Diluted Weighted Average Shares | 11.3078 | 11.3039 | 11.2675 | 11.2655 | 11.2552 |
Diluted EPS Excluding Extraordinary Items | -0.99878 | -0.80017 | -3.45836 | -0.68271 | -0.75867 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.99878 | -0.80017 | -0.8387 | -0.68271 | -0.75867 |
Unusual Expense (Income) | 29.517 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 86.146 | 93.112 | 169.435 | 6.975 | 23.236 |
Cash and Short Term Investments | 84.37 | 91.229 | 168.598 | 6.181 | 21.867 |
Cash & Equivalents | 24.127 | 35.724 | 168.598 | 6.181 | 19.371 |
Short Term Investments | 60.243 | 55.505 | 0 | 2.496 | |
Prepaid Expenses | 1.163 | 1.883 | 0.787 | 0.744 | 1.369 |
Total Assets | 113.29 | 172.596 | 203.157 | 6.975 | 23.521 |
Property/Plant/Equipment, Total - Net | 7.869 | 8.89 | 2.3 | 0 | 0.263 |
Property/Plant/Equipment, Total - Gross | 8.352 | 9.126 | 2.419 | 0 | 1.09 |
Accumulated Depreciation, Total | -0.483 | -0.236 | -0.119 | 0 | -0.827 |
Other Long Term Assets, Total | 1.389 | 1.61 | 1.905 | 0 | 0.022 |
Total Current Liabilities | 5.74 | 4.298 | 2.915 | 0.583 | 3.078 |
Accounts Payable | 1.586 | 0.954 | 0.914 | 0.263 | 0.441 |
Accrued Expenses | 4.154 | 3.344 | 2.001 | 0.32 | 2.637 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 11.207 | 10.682 | 3.914 | 0.583 | 3.078 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 102.083 | 161.914 | 199.243 | 6.392 | 20.443 |
Common Stock | 0.011 | 0.011 | 0.011 | 0 | 0.019 |
Additional Paid-In Capital | 262.724 | 256.126 | 245.992 | 213.388 | 209.366 |
Retained Earnings (Accumulated Deficit) | -159.964 | -94.012 | -46.76 | -225.462 | -210.47 |
Other Equity, Total | -0.688 | -0.211 | 0.003 | 0.005 | |
Total Liabilities & Shareholders’ Equity | 113.29 | 172.596 | 203.157 | 6.975 | 23.521 |
Total Common Shares Outstanding | 11.2674 | 11.2357 | 11.2118 | 0.55763 | 0.48109 |
Redeemable Preferred Stock | 18.463 | 21.523 | |||
Other Current Assets, Total | 0.127 | 0 | 0.05 | 0.05 | |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Total Preferred Shares Outstanding | 0.00803 | 0.00803 | 0.00803 | 0.01895 | |
Goodwill, Net | 0 | 29.517 | 29.517 | ||
Other Liabilities, Total | 5.467 | 6.384 | 0.999 | ||
Long Term Investments | 17.886 | 39.467 | |||
Total Receivables, Net | 0.486 | ||||
Accounts Receivable - Trade, Net | 0.486 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 77.813 | 84.265 | 94.616 | 86.146 | 98.667 |
Cash and Short Term Investments | 74.034 | 80.36 | 86.61 | 84.37 | 96.317 |
Cash & Equivalents | 33.768 | 33.978 | 21.035 | 24.127 | 47.498 |
Short Term Investments | 40.266 | 46.382 | 65.575 | 60.243 | 48.819 |
Prepaid Expenses | 3.498 | 3.56 | 7.388 | 1.163 | 1.97 |
Other Current Assets, Total | 0.002 | 0.001 | 0.127 | 0.127 | 0 |
Total Assets | 88.467 | 95.141 | 106.405 | 113.29 | 148.591 |
Property/Plant/Equipment, Total - Net | 6.968 | 7.25 | 7.565 | 7.869 | 8.168 |
Goodwill, Net | 0 | 29.517 | |||
Long Term Investments | 0 | 0 | 2.893 | 17.886 | 10.76 |
Other Long Term Assets, Total | 3.686 | 3.626 | 1.331 | 1.389 | 1.479 |
Total Current Liabilities | 6.775 | 4.932 | 6.41 | 5.74 | 3.711 |
Accounts Payable | 2.504 | 1.852 | 4.081 | 1.586 | 0.456 |
Accrued Expenses | 4.271 | 3.08 | 2.329 | 4.154 | 3.255 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11.511 | 9.916 | 11.637 | 11.207 | 9.413 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 4.736 | 4.984 | 5.227 | 5.467 | 5.702 |
Total Equity | 76.956 | 85.225 | 94.768 | 102.083 | 139.178 |
Common Stock | 0.011 | 0.011 | 0.011 | 0.011 | 0.011 |
Additional Paid-In Capital | 267.273 | 265.853 | 264.235 | 262.724 | 261.294 |
Retained Earnings (Accumulated Deficit) | -190.163 | -180.303 | -169.009 | -159.964 | -120.997 |
Other Equity, Total | -0.165 | -0.336 | -0.469 | -0.688 | -1.13 |
Total Liabilities & Shareholders’ Equity | 88.467 | 95.141 | 106.405 | 113.29 | 148.591 |
Total Common Shares Outstanding | 11.3649 | 11.308 | 11.3068 | 11.2674 | 11.2674 |
Total Preferred Shares Outstanding | 0.00799 | 0.00803 | 0.00803 | 0.00803 | 0.00803 |
Total Receivables, Net | 0.279 | 0.344 | 0.491 | 0.486 | 0.38 |
Accounts Receivable - Trade, Net | 0.279 | 0.344 | 0.491 | 0.486 | 0.38 |
Preferred Stock - Non Redeemable, Net | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.952 | -47.252 | -33.978 | -14.992 | -20.729 |
Cash From Operating Activities | -26.457 | -34.502 | -23.407 | -15.646 | -23.233 |
Cash From Operating Activities | 0.248 | 0.117 | 0.103 | 0.279 | 0.115 |
Non-Cash Items | 38.708 | 13.149 | 9.839 | 0.956 | 3.402 |
Changes in Working Capital | 0.539 | -0.516 | 0.629 | -1.889 | -6.021 |
Cash From Investing Activities | 14.95 | -98.194 | 2.835 | 2.484 | 18.427 |
Capital Expenditures | -0.12 | -0.596 | -0.884 | -0.016 | -0.119 |
Other Investing Cash Flow Items, Total | 15.07 | -97.598 | 3.719 | 2.5 | 18.546 |
Cash From Financing Activities | -0.09 | -0.228 | 189.401 | 0 | 2.985 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | -0.09 | -0.228 | 191.07 | 0 | 2.985 |
Foreign Exchange Effects | 0 | 0.022 | |||
Net Change in Cash | -11.597 | -132.924 | 168.829 | -13.162 | -1.799 |
Cash Interest Paid | 0 | 0 | 0.034 | ||
Issuance (Retirement) of Debt, Net | 0 | -1.669 | |||
Cash Taxes Paid | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.045 | -65.952 | -26.985 | -19.294 | -10.755 |
Cash From Operating Activities | -12.888 | -26.457 | -21.431 | -16.084 | -10.961 |
Cash From Operating Activities | 0.077 | 0.248 | 0.173 | 0.109 | 0.056 |
Non-Cash Items | 1.845 | 38.708 | 7.311 | 5.26 | 2.289 |
Cash Interest Paid | 0 | ||||
Changes in Working Capital | -5.765 | 0.539 | -1.93 | -2.159 | -2.551 |
Cash From Investing Activities | 9.86 | 14.95 | 33.295 | 14.247 | 0.745 |
Capital Expenditures | -0.006 | -0.12 | -0.114 | -0.031 | -0.011 |
Other Investing Cash Flow Items, Total | 9.866 | 15.07 | 33.409 | 14.278 | 0.756 |
Cash From Financing Activities | -0.064 | -0.09 | -0.09 | -0.072 | -0.072 |
Issuance (Retirement) of Stock, Net | -0.064 | -0.09 | -0.09 | -0.072 | -0.072 |
Net Change in Cash | -3.092 | -11.597 | 11.774 | -1.909 | -10.288 |
Issuance (Retirement) of Debt, Net | |||||
Cash Taxes Paid | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Opaleye Management Inc. | Hedge Fund | 23.7671 | 2692594 | 0 | 2023-06-30 | MED |
Shefferman (Jesse M) | Individual Investor | 7.1714 | 812454 | -9310 | 2023-06-27 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 6.8195 | 772584 | -20974 | 2023-06-30 | LOW |
Marshall (Randall S) | Individual Investor | 5.169 | 585600 | 0 | 2023-04-11 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7745 | 427612 | 0 | 2023-06-30 | LOW |
Medical Strategy GmbH | Investment Advisor | 2.2512 | 255044 | -41727 | 2023-05-31 | MED |
Boxer Capital, L.L.C. | Hedge Fund | 1.8468 | 209227 | 0 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 1.7625 | 199671 | 0 | 2023-06-30 | LOW |
Beshar (Luke M) | Individual Investor | 1.7477 | 198000 | 0 | 2023-04-11 | LOW |
Ikarian Capital LLC | Hedge Fund | 1.6653 | 188664 | 0 | 2023-06-30 | HIGH |
Privium Fund Management (UK) Ltd | Investment Advisor | 1.0568 | 119730 | 0 | 2023-06-30 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.7379 | 83600 | 24694 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7363 | 83420 | 0 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.5831 | 66063 | -1300 | 2023-06-30 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.5649 | 64000 | 0 | 2023-06-30 | MED |
Zummo (Jacqueline) | Individual Investor | 0.4484 | 50799 | -3824 | 2023-04-11 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2922 | 33101 | -854 | 2023-06-30 | LOW |
Garceau (Roger J) | Individual Investor | 0.2913 | 33000 | 0 | 2023-04-11 | LOW |
Levy (Richard S) | Individual Investor | 0.2736 | 31000 | 0 | 2023-04-11 | LOW |
Sargen (Gregory P) | Individual Investor | 0.2736 | 31000 | 0 | 2023-04-11 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Protara Therapeutics, Inc. Company profile
About Protara Therapeutics Inc
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Protara Therapeutics Inc revenues was not reported. Net loss increased 39% to $47.3M. Higher net loss reflects Research and development - other increase of 75% to $19.7M (expense), General and administrative - other increase of 30% to $17.4M (expense), Stock-based Compensation in Research and increase of 90% to $1.4M (expense).
Industry: | Bio Therapeutic Drugs |
345 Park Avenue South
3rd Floor
NEW YORK
NEW YORK 10010
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com